At the news
? BULLISHIMPACT 8/10 8-K filed Apr 13, 2026 at 20:44 ET
Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first and only FDA-approved treatment for FSGS, expanding FILSPARI's label beyond IgA nephropathy.
- FDA approved FILSPARI for FSGS without nephrotic syndrome in patients aged 8 and older
- FILSPARI is the first and only FDA-approved treatment for FSGS
- Approval expands FILSPARI's label beyond IgA nephropathy into a second rare kidney disease
- Phase 3 DUPLEX study showed 48% reduction in proteinuria vs 27% for irbesartan in non-nephrotic FSGS patients
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access